Are you looking for a viable alternative to Infuse
®
?
New research in The Journal of Neurosurgery presents an option.
*Corresponding author, Dr. McGirt is a paid consultant of Bioventus. This research was funded by Bioventus. Retrospective analysis of data recorded by CNSA in their registry. Recorded data are from a single site.
†
In vitro performance
may not be predictive of performance in humans.
1
Daffner SD, Bunch JT, Burton DC, et al. Better functional recovery after single-level compared with two-level posterolateral lumbar fusion. Cureus. 2022;14(3):e23010. doi:10.7759/
cureus.23010.
Bioventus, the Bioventus logo, and OSTEOAMP are registered trademarks of Bioventus LLC. OSTEOAMP may be used in situations where an autograft is appropriate. It should be restricted to homologous use for the repair, replacement
or reconstruction of musculoskeletal defects. See full prescribing information at bioventussurgical.com.
Infuse is a registered trademark of Medtronic.
©
2024
Bioventus
LLC
|
SMK-005718
|
08/24
A versatile allograft backed by peer-reviewed evidence.
Innovations for Active Healing
A new Level II study, led by Primary Investigator Dr. Matthew McGirt*
from Carolina Neurosurgery and Spine Associates, compared
fusion between Infuse and OSTEOAMP
®
in single or multilevel TLIF/
PLIF procedures. In the study of 1,154 patients (654 treated with
OSTEOAMP, 500 with rhBMP-2) with follow-up at 12 and 24 months,
investigators reported that OSTEOAMP provides a viable alternative
to Infuse.
†
This differentiated allograft is available in multiple formats
with distinct properties to meet specific surgical needs.
Read the Study in Journal of NeuroSurgery
BVS-Surgical.com/McGirtStudy ›
OSTEOAMP Meets Your Needs
Robust
1
peer-reviewed clinical
evidence supporting efficacy.
Approved for use in both cervical
and lumbar spine applications.
Approvals in most major health
systems and GPOs across U.S.
Shelf-stable allograft, ready-to-use,
plus unparalleled handling .
OSTEOAMP for Your Patients
SurgicalMarketing@Bioventus.com ›
Beckers Full Page 8.375x10.875 r07.indd 1 Beckers Full Page 8.375x10.875 r07.indd 1 8/28/24 12:16 PM 8/28/24 12:16 PM
